Product overview

Name: ICG 001  
Cat No: HB0331  
Short description: Selective, competitive inhibitor of β-catenin/CBP interaction  
Biological description: Selective and competitive inhibitor of β-catenin/CREB-binding protein (CBP) interaction (IC50 = 3.0 µM). Exhibits little activity on β-catenin/p300. Also inhibits TGF-β1 induced α-SMA induction. Displays cardioprotective and apoptosis inducing properties.  
Biological action: Inhibitor  
Purity: >98%

Properties

Chemical name: (6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyraino[1,2-a]pyrimidine-1(6H)-carboxamide  
Molecular Weight: 548.63  
Chemical structure: ![Chemical structure of ICG 001]

Molecular Formula: C33H32N4O4  
CAS Number: 847591-62-2

Storing and Using Your Product

Storage instructions: -20°C  
Solubility overview: soluble in DMSO (100mM) or ethanol (50mM)  
Important: This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for ICG 001
The small molecule Wnt signaling modulator ICG-001 improves contractile function in chronically infarcted rat myocardium.
PubMedID: 24069374

ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription.
PubMedID: 16787331

A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].
PubMedID: 15314234

Interactions between β-catenin and transforming growth factor-β signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP)
PubMedID: 22241478